Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2012. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility (PDMR), and their connected persons, specifically regarding awards under the GlaxoSmithKline 2009 Share Value Plan (SVP).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider transactions rather than a financial performance report.
Material Changes and Transactions
On August 22, 2012, awards were made under the SVP resulting in the following changes in interests:
- Mr. P Thomson: Received 2,835 Ordinary Shares.
- Dr. M Slaoui (Executive Director): Received 2,300 American Depositary Shares (ADSs).
The awards were based on an Ordinary Share price of £14.425 and an ADS price of $45.86, reflecting the closing middle market price on August 22, 2012.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly details the notification of share awards in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Investor Verification Points
- Verify the specific number of Ordinary Shares and ADSs awarded to Mr. P Thomson and Dr. M Slaoui.
- Confirm the share price basis (£14.425 per Ordinary Share and $45.86 per ADS) used for the August 22, 2012 awards.
- Review the full GlaxoSmithKline 2009 Share Value Plan terms to understand vesting conditions and future dilution implications.